Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$4.6M
8M shares
52-week range
$0.41 – $1.65
10% from low
Exchange
NASDAQ
CS
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
www.galmedpharma.comNo one on the platform currently holds GLMD.
No tracked institution reports a position in GLMD as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-08-30 | 1-for-12reverse |
| 2023-05-15 | 1-for-15reverse |
No one on the platform has traded GLMD yet.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $6M | +1.0% | $-1.56 | $-1.56–$-1.56 | — | 1 |
| 2027 | $6M | +1.4% | $-0.90 | $-0.90–$-0.90 | — | 1 |
| 2028 | $5M | -13.8% | $-0.76 | $-0.76–$-0.76 | — | 1 |
| 2029 | $17M | +248.8% | $-1.81 | $-1.81–$-1.81 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-08 | $-0.38 | $-0.29 | +23.7% |
| 2026-03-31 | $-0.51 | $-0.92 | -80.4% |
| 2025-11-26 | $-0.54 | $-0.33 | +38.9% |
| 2025-08-28 | $-0.83 | $-0.63 | +24.1% |
| 2025-05-22 | $-0.89 | $-0.62 | +30.3% |
| 2025-04-02 | $-0.89 | $-1.94 | -118.0% |
| $4M |
| — |
| INMInMed Pharmaceuticals Inc. | $1.43 | +0.70% | $3M | — |
| ISPCiSpecimen Inc. | $2.30 | +1.32% | $319383 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$GLMD We retail can't pass anything. But I just mailed mine. Voted against the name change. As a statement vote. If it passes. Which it will. Then after five years I'm outta here. They're cowards if they run away from their very name. If I was running this company I would pay for my own stamps for the mailing, and save the money for trials. BTW, how much are those other Directors paying themselves for this performance? GLTA
View on StockTwits ↗$GLMD yall buy some SpaceX at below ipo price and like this forget about it for 20 years and leave it to your kids. Not advice. Just sayin.
View on StockTwits ↗$RLMD lot of bio stocks curling up….$BEAT $ONCO $GLMD
View on StockTwits ↗$GLMD Could be in for a long long time to come !! Institutional interest is almost ZERO here. No confidence from institutions as well as from insiders. Our exit plan is solely on MMs game ! So make sure you keep on eye on Institutional filings. If they stay away from this company, then you should know about the nature of any upside move !
View on StockTwits ↗$SLS congrats sella bulls. You guys deserve it. Hope the story keeps getting sweeter. Here. I have a feeling $ONCO and $GLMD will be on a similar route soon. Good luck
View on StockTwits ↗$GLMD Can I get at least one like? Don't want Stocktwits new algorithms to bury me! LOL Seems like that is their new game. Btw. Again. As always! GLTA. If we ever quit laughing it's all over. LM
View on StockTwits ↗$GLMD Guys I've changed my mind. Maybe. A new name might cheer me up. LOL Despite my losses. Even if means Allen is going to divert trial funds for a lot of new stationary. Personally. For the record. I think Foucie. (Sp?) Looks like a saint when compared to Allen.
View on StockTwits ↗$GLMD Annual meeting shareholder vote is out. Yay or nay on the name change?
View on StockTwits ↗$GLMD This Allen is a Genius Take millions of Dollars for nothing 🤡the best Manipulation Guy in History 🤦💩
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.